Mira Pharma reports preclinical study showing Mira-55 reduces anxiety-like behavior, differs from THC mechanism

MIRA Pharmaceuticals, Inc.

MIRA Pharmaceuticals, Inc.

MIRA

0.00
  • Mira Pharmaceuticals released new preclinical data on Mira-55, a cannabinoid analog being developed for chronic inflammatory pain.
  • Results were presented now, not scheduled for a future meeting, based on standard animal pharmacology tests comparing Mira-55 with THC.
  • Mira-55 showed anxiety-reducing activity, while THC did not, supporting a differentiated behavioral profile.
  • Testing also indicated Mira-55 did not produce the typical THC-like central nervous system effects, supporting continued development toward an IND submission.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mira Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-030033), on June 25, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.